Figure 1
From: EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
Low EHD2 expression is associated with TNBC patients. (a) Representative EHD2 immunohistochemistry staining on sections of human breast tumor (TMA). Scale bar = 100 μm. (b) Quantification of EHD2 H-score (immunohistochemistry intensity multiplied by percentage of positively stained cells) in luminal, HER2+ and TNBC tissues. (c) Quantification of EHD2 H-score (immunohistochemistry intensity multiplied by percentage of positively stained cells) in stroma cells of luminal, HER2+ and TNBC tissues. (d) EHD2 protein levels and standard clinicopathological parameters in a series of 377 breast cancers (TMA). Underexpressed EHD2 corresponds to EHD2 H-score <50 whereas overexpressed EHD2 correspond to EHD2 H-score ≥50. ns = non-significant; *P < 0.05; **P < 0.01; ***P < 0.001; (b) Bonferroni’s multiple comparison test; mean ± s.e.m.
